Clinical trial
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine…
NCT00319098 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00319098 |
|---|---|
| Title | Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above |
| Official title | A Phase III, Observer-blind, Randomised Study to Evaluate the Safety and Immunogenicity of One and Two Administrations of Pandemic Monovalent (H5N1) Influenza Vaccine (Adjuvanted Split Virus Formulation) in Adults Aged 18 Years and Older |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Adjuvanted pandemic influenza candidate vaccine, Fluarix, Placebo |
| Enrollment | 5,075 |
| Start date | May 1, 2006 |
| Primary completion | Jan 1, 2007 |
| Completion | Jul 31, 2007 |
| First posted | Apr 27, 2006 |
| Last update posted | Jul 23, 2018 |
| Countries | Estonia, France, Germany, Netherlands, Russia, Spain, Sweden |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: